Acute myeloid leukemia in elderly patients: New targets, new therapies
نویسندگان
چکیده
Prior to the past few years, development of new therapies for acute myeloid leukemia (AML) has been disappointingly slow. For several decades, standard therapy AML consisted intensive induction chemotherapy, and potentially a subsequent hematopoietic stem cell transplant. Unfortunately, older patients are less responsive to, frequently unfit tolerate, such chemotherapy. Given that majority elderly, this population most affected by lack newer toxic therapies. However, in recent treatment landscape dramatically shifted with approval many drugs. As summarized review, these drugs targeted agents better tolerated than chemotherapy could substantially benefit elderly patients. Although drug resistance remains major concern, options more numerous ever before, bringing promise improved patient outcomes.
منابع مشابه
Acute Myeloid Leukaemia: New Targets and Therapies
The most common acute hematological malignancy in adults is acute myeloid leukaemia (AML), accounting for more than 80% of cases in patients over 60 years of age [...].
متن کاملAcute Myeloid Leukemia in the Elderly Patient: New Strategies
Although selected older adults with acute myeloid leukemia can benefit from intensive therapies, recent evidences support the use of lower-intensity therapies (hypomethylating agents or low-dose cytarabine) in most of these patients and emphasize the importance of tolerability and quality of life. Individualized approaches to treatment decision-making beyond consideration of chronologic age alo...
متن کاملSurvival in elderly acute myeloid leukemia patients.
We read with interest the paper by Pulsoni et al. on survival in unselected elderly patients. We would like to back their conclusions with a brief presentation of our data. Between 1992 and 2003, 159 non-M3 AML patients over 60 years were diagnosed and treated in our institution. 34 patients (21.9%) were treated with aggressive induction chemotherapy (daunorubicin/idarubicin + cytarabine ± etop...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Aging and cancer
سال: 2023
ISSN: ['2643-8909']
DOI: https://doi.org/10.1002/aac2.12065